Cognitive Decline in Alzheimer's Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting.
Saved in:
| Title: | Cognitive Decline in Alzheimer's Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting. |
|---|---|
| Authors: | Euesden J; GlaxoSmithKline Medicines R&D, Stevenage, Hertfordshire SG1 2NY, UK., Gowrisankar S; Parexel International, 2520 Meridian Parkway, Durham, NC 27713, USA., Qu AX; Parexel International, 2520 Meridian Parkway, Durham, NC 27713, USA., Jean PS; Parexel International, 2520 Meridian Parkway, Durham, NC 27713, USA., Hughes AR; Parexel International, 2520 Meridian Parkway, Durham, NC 27713, USA., Pulford DJ; GlaxoSmithKline Medicines R&D, Stevenage, Hertfordshire SG1 2NY, UK. |
| Source: | Genes [Genes (Basel)] 2020 May 02; Vol. 11 (5). Date of Electronic Publication: 2020 May 02. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4425 (Electronic) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2073-4425 |
|---|---|
| DOI: | 10.3390/genes11050501 |
